Sermorelin vs Tesamorelin

Both of these molecules are GHRH analogs, but they were studied in completely different populations and that shapes how the comparison reads. Sermorelin is the original GHRH(1-29) fragment, with most of its data coming from age-related GH-deficiency work and pediatric short-stature studies. Tesamorelin is a stabilized GHRH analog approved specifically for HIV-associated lipodystrophy and studied at length for visceral fat reduction. The mechanism is the same; the studied use cases are not.

Half-life is the structural difference between the two. Sermorelin's half-life is on the order of 10–20 minutes; tesamorelin's modified structure stretches it to roughly 30 minutes to an hour, with effective biological action longer than the raw plasma half-life suggests. Both molecules are typically administered daily in their respective protocols, but the dose magnitudes are different — tesamorelin protocols usually sit around 1–2 mg daily while sermorelin protocols are often in the 100–500 mcg range.

In a log the two molecules look more different than the shared mechanism would suggest. Tesamorelin logs frequently include a waist-circumference field because the published evidence base is so heavily weighted toward visceral-fat measurements. Sermorelin logs tend to focus on sleep quality, morning energy, and recovery markers because that is how the off-label use case is usually framed. Both molecules log cleanly as a single daily event.

Reconstitution mechanics are identical, but the unit math on a 100-unit syringe is quite different because tesamorelin's per-dose milligrams are roughly 4–10x sermorelin's. A 5 mg tesamorelin vial reconstituted with 2 mL hits 2.5 mg/mL, which puts a 1 mg dose at 0.4 mL or 40 units; a 5 mg sermorelin vial at the same concentration puts a 200 mcg dose at 0.08 mL or 8 units. The mg-to-units calculator linked below handles either once vial concentration is set.

For the Sermorelin vs Tesamorelin decision specifically, the calendar shape is what most readers underweight. Sermorelin's example vial is 5 mg drawn against 0.2 mg per dose at 7 doses per week. Tesamorelin's example vial is 5 mg drawn against 1 mg per dose at 7 doses per week. Those four numbers feed every column in the table above; change any one and the sermorelin vs tesamorelin comparison shifts with it.

Concentration in this pair: Sermorelin sits at 2.50 mg/mL on the example reconstitution; Tesamorelin sits at 2.50 mg/mL on its example. That single ratio is what determines how many U-100 syringe units a given dose of either molecule actually draws, so it is the first thing to confirm before treating any "Sermorelin vs Tesamorelin" unit number on the internet as authoritative.

Doses per vial in this matchup work out to roughly 25 for Sermorelin and 5 for Tesamorelin at the example dose sizes, with vial-duration windows near 3.6 weeks and 0.7 weeks respectively. Refill cadence follows directly from those windows, which is why the sermorelin vs tesamorelin pair shows up in planning conversations more than in pure mechanism conversations.

When readers compare Sermorelin against Tesamorelin, the Sermorelin-side mistakes that show up most in logs are: Mistaking its short half-life for a lack of activity and consequently attempting to use multi-day dosing intervals. Dosing in the morning, which works against the body's natural GH circadian rhythm and the peptide's designed function. Assuming it operates identically to longer-acting GHRH analogs and failing to maintain a rigid nightly administration schedule. Using a very low diluent volume, such as 0.5 mL, which makes the accurate measurement of a typical 200 mcg dose exceedingly difficult on a U-100 syringe. Each of these gets amplified when a reader is also actively comparing against Tesamorelin, because muscle memory from one molecule's unit math leaks into the other.

Sermorelin question worth answering up front — Why is Sermorelin composed of only the first 29 amino acids of GHRH? Sermorelin is structured as the N-terminal fragment of native Growth Hormone-Releasing Hormone because extensive research identified this segment as the biologically active region. These 29 amino acids are sufficient for binding to and stimulating the GHRH receptor with the same efficacy as the full 44-amino-acid hormone. The remaining C-terminal portion of the natural peptide is not required for this primary function.

Sermorelin question worth answering up front — What is meant by a 'pulse-preserving' stimulus in the context of Sermorelin? This term describes how Sermorelin's rapid action and clearance imitate a natural GHRH signal from the brain. It causes a discrete, short-lived release of GH from the pituitary, after which the peptide is quickly eliminated from the system. This mechanism allows the body's own regulatory feedback loops and subsequent natural GH pulses to function without interference, in contrast to the sustained hormone levels produced by direct GH administration.

On the Tesamorelin side of the Sermorelin vs Tesamorelin decision, the recurring mistakes are: Assuming the per-dose volume and syringe draw will be as small as sermorelin's and failing to plan for a larger subcutaneous injection. Neglecting to systematically document and rotate injection sites, which can lead to localized lipohypertrophy that interrupts a planned daily schedule. Mistaking the typical milligram (mg) dose for micrograms (mcg) in the calculator, leading to a thousand-fold dosing error. Attempting to reconstitute a 5 mg vial with an excessively small diluent volume, making the large 1 mg dose difficult to measure and draw accurately. These are not generic dosing slips — they are the ones that compound when Tesamorelin is being logged in parallel with Sermorelin.

Tesamorelin question worth answering up front — Why is the Tesamorelin dose in milligrams (mg) when other GHRH analogs are often dosed in micrograms (mcg)? Tesamorelin's milligram-level dosing is a function of its molecular structure and the extensive clinical research that established its use profile. As the full 44-amino-acid GHRH sequence, its molecular weight and receptor affinity necessitate a larger mass to achieve the desired level of pituitary stimulation. The protocols for its FDA-approved indication were developed around a 1 mg or 2 mg daily dose, reflecting its distinct pharmacology compared to smaller, truncated peptide fragments.

Tesamorelin question worth answering up front — What specifically is the purpose of the trans-3-hexenoyl group on Tesamorelin? The trans-3-hexenoyl group is a fatty acid-based modification chemically bonded to the start of the peptide chain. Its sole purpose is to serve as a physical shield, sterically hindering the enzyme DPP-IV from accessing its cleavage site on the GHRH sequence. This protection from enzymatic degradation is what grants Tesamorelin a significantly longer half-life compared to native GHRH, which is its primary design advantage.